Multiple Myeloma Hub

Global online platform providing the latest treatment options & medical information on #MultipleMyeloma. Intended for HCPs.

[Multiple Myeloma Hub @MM_Hub]

🎥 Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE, discusses strategies for managing ocular toxicities associated with belantamab mafodotin in patients with #MultipleMyeloma.

Watch the full video here: https://t.co/VwUXnUMDDc

#myeloma #mmsm #MedEd #MedNews

[Multiple Myeloma Hub @MM_Hub]

New publication 📝 The BRIDGE-2M consensus, published in @AdvancesTherapy, links five patient-specific attributes to individualized bridging therapy objectives for patients with RRMM awaiting CAR T-cell therapy.

Learn more about RRMM: https://t.co/Rg76uGTotr

#MultipleMyeloma #myeloma #mmsm #MedEd @RahulBanerjeeMD

[Multiple Myeloma Hub @MM_Hub]

🚨 NEWS 🚨

A biologics license application has been submitted to the @FDA for etentamig, a second-generation BCMA-directed bispecific antibody, for the treatment of RRMM. This application is supported by results from the phase III CERVINO trial.

Read more: https://t.co/lF8vb6OK8a

#MultipleMyeloma #myeloma #mmsm #MedEd #MedNews

[Multiple Myeloma Hub @MM_Hub]

🎥 The Multiple Myeloma Hub spoke with Fredrik Schjesvold about the current use of belantamab mafodotin in clinical practice for MM, including its positioning alongside other treatment options.

Watch the interview: https://t.co/jCbcc2CjP0

#MultipleMyeloma #myeloma #mmsm #MedEd @MyelomaOslo

Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

[Multiple Myeloma Hub @MM_Hub]

🎥 The Multiple Myeloma Hub was pleased to speak with Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE. We asked, How are ocular toxicities associated with belantamab mafodotin managed in MM?

Watch the full video here: https://t.co/qnzlnr8e7N

#MultipleMyeloma #myeloma #mmsm #MedEd #MedNews

Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence.

[Multiple Myeloma Hub @MM_Hub]

New publication 📝 Results from the final survival analysis of the phase III MAIA trial, published in @LeukemiaJnl, show that after >7 years of follow-up, median OS was 90.3 months with DRd vs 64.1 months with Rd in transplant-ineligible patients with NDMM (HR, 0.67; 95% CI, 0.55–0.82).

Learn more about NDMM: https://t.co/5GqK9e2Q1R

#MultipleMyeloma #myeloma #mmsm #MedEd

[Multiple Myeloma Hub @MM_Hub]

🚨 News 🚨

Japan’s Ministry of Health, Labour and Welfare (MHLW) approves an on-body injector (OBI) delivery system for the subcutaneous administration of isatuximab, in combination with approved standard-of-care regimens, for the treatment of adults with MM.

Read more: https://t.co/3rPXZTvgZ5

#MultipleMyeloma #myeloma #mmsm #MedEd #MedNews

[Multiple Myeloma Hub @MM_Hub]

🚨 News 🚨

@EMA_News CHMP recommends the approval of an indication extension for talquetamab to include its use in combination with daratumumab ± pomalidomide for the treatment of adults with RRMM who have received ≥1 prior LoT; based on results from the phase III MonumenTAL-3 study.

Read more: https://t.co/wTbpfusFZt

#MultipleMyeloma #myeloma #mmsm #MedEd #MedNews

[Multiple Myeloma Hub @MM_Hub]

🚨 It’s the final day of #IACH2026!

There’s still plenty to come as the meeting draws to a close. Follow our social media channels for the latest congress content and updates from the final day.

Visit the Multiple Myeloma Hub to catch up on our coverage and explore highlights from IACH 2026.

https://t.co/O697dhp8wg

#MultipleMyeloma #myeloma #mmsm

[Multiple Myeloma Hub @MM_Hub]

This year, the myeloma community defined what a cure looks like for the first time. The latest issue of @themmrf Accelerator looks at the research driving that progress: https://t.co/q8WAcaQTcI

[Multiple Myeloma Hub @MM_Hub]

Do you want to stay up to date with the latest insights and discussions on multiple myeloma?

Subscribe to the Multiple Myeloma Hub podcast channel to stream, listen to, and download your favorite episodes.

🎧 Find us on Apple Music, Spotify, and Amazon Music!

#MMsm

[Multiple Myeloma Hub @MM_Hub]

Catch up on the latest developments in multiple myeloma and other PCDs from #IACH2026, with live social media coverage from the Multiple Myeloma Hub:
https://t.co/3veMBuAPZZ

#MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #IACH2026 | POSTER

Slama Ahlem, University of Monastir, presented results from a single-center, retrospective study comparing outcomes of VMP-based regimens in patients with MM aged ≥75 vs <75 years (N = 53).

No significant differences were observed between age groups in ORR (p = 0.686), ≥VGPR rate (p = 0.210), 1-year OS (p = 0.546) or 1-year RFS (p = 0.817). These findings support the use of VMP in patients aged ≥75 years with MM.

Follow our live feed for more updates: https://t.co/LpMLeUSjDx

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @TheIACH

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #IACH2026 | POSTER

Slama Ahlem, University of Monastir, presented results from a single-center, retrospective study evaluating the impact of inaugural extramedullary disease (EMD) in elderly patients with NDMM treated with VMP (N = 53). EMD was identified in 10 patients (19%).

After induction, the ORR (p = 0.67) and ≥VGPR rate (p = 0.70) were comparable between the EMD and non-EMD groups. With a median follow-up of 56 months, 3-year OS was 85% in the non-EMD group vs 67% in the EMD group (p = 0.462); 3-year PFS was 89% vs 74%, respectively (p = 0.039).

Follow our live feed for more updates: https://t.co/LpMLeUSjDx

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @TheIACH

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #IACH2026 | POSTER

Slama Ahlem, University of Monastir, presented results from a single-center, retrospective study evaluating the efficacy and safety of VMP-based regimens in elderly, transplant-ineligible patients with NDMM (N = 53).

The ORR was 55%, with ≥VGPR reported in 23% of patients. The most common TEAEs were pulmonary infections, thrombocytopenia, neutropenia, and peripheral neuropathy.

Follow our live feed for more updates: https://t.co/LpMLeUSjDx

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#MultipleMyeloma #myeloma #mmsm #MedEd @TheIACH

[Multiple Myeloma Hub @MM_Hub]

🎧 In our latest podcast, Adam Cohen discusses FcRH5 as a therapeutic target in #MultipleMyeloma, the rationale for sequential and simultaneous antigen-targeting strategies, patients who may potentially benefit from these approaches, and emerging data on cevostamab.

Listen here: https://t.co/DCz8EG51D3

#myeloma #mmsm #MedEd @CohenAd_MMdoc

Intended for healthcare professionals. Independently supported by Roche. Funders are allowed no influence.

[Multiple Myeloma Hub @MM_Hub]

Just 1 day to go!

The Multiple Myeloma Hub is getting ready for #IACH2026, taking place in Paris and online.

📅 October 15–17
📍 Paris, France & online

Follow our social media channels for congress coverage and the latest updates in multiple myeloma.

#MultipleMyeloma #myeloma #mmsm

[Multiple Myeloma Hub @MM_Hub]

🎧 In our latest podcast, María-Victoria Mateos discusses ≥5-year findings from CARTITUDE-2 Cohort A, including long-term survival and safety with a single cilta-cel infusion.

Listen here: https://t.co/IhFJ91f8RC

#MultipleMyeloma #mmsm #MedEd

Intended for healthcare professionals only. Independently supported by Legend Biotech. Funders are allowed no influence.